472
Views
5
CrossRef citations to date
0
Altmetric
Review Articles

Characteristics of SARS-CoV2 that may be useful for nanoparticle pulmonary drug delivery

, , , , &
Pages 233-243 | Received 17 May 2021, Accepted 18 Aug 2021, Published online: 29 Aug 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

S. Swathi Krishna, M. S. Sudheesh & Vidya Viswanad. (2023) Liposomal drug delivery to the lungs: a post covid-19 scenario. Journal of Liposome Research 33:4, pages 410-424.
Read now

Articles from other publishers (4)

Andreas Petersen, Oguz Han Asnaz, Benjamin Tadsen & Franko Greiner. (2022) Decoupling of dust cloud and embedding plasma for high electron depletion in nanodusty plasmas. Communications Physics 5:1.
Crossref
Akshad Balde, Se-Kwon Kim, Soottawat Benjakul & Rasool Abdul Nazeer. (2022) Pulmonary drug delivery applications of natural polysaccharide polymer derived nano/micro-carrier systems: A review. International Journal of Biological Macromolecules 220, pages 1464-1479.
Crossref
Jiefeng Zhao, Jinfeng Zhu, Chao Huang, Xiaojian Zhu, Zhengming Zhu, Qinrong Wu & Rongfa Yuan. (2022) Uncovering the information immunology journals transmitted for COVID-19: A bibliometric and visualization analysis. Frontiers in Immunology 13.
Crossref
Mohamed Abbas, Mohammed S. Alqahtani, Hussain M. Almohiy, Fawaz F. Alqahtani, Roaa Alhifzi & Layal K. Jambi. (2021) The Potential Contribution of Biopolymeric Particles in Lung Tissue Regeneration of COVID-19 Patients. Polymers 13:22, pages 4011.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.